Zai Lab Presented Data From Ongoing Phase 1a/1b Study Of Zl-1310 At EORTC-NCI-AACR Symposium 2024 For Previously Treated Extensive-Stage Small Cell Lung Cancer After At Least One Prior Platinum-based Chemotherapy Regimen
Portfolio Pulse from Benzinga Newsdesk
Zai Lab presented promising data from its Phase 1a/1b study of ZL-1310 for extensive-stage small cell lung cancer, showing a 74% objective response rate and favorable safety profile.
October 24, 2024 | 9:27 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Zai Lab's ZL-1310 demonstrated a 74% objective response rate in a Phase 1a/1b study for extensive-stage small cell lung cancer, with favorable pharmacokinetics and safety profile, supporting further evaluation.
The high objective response rate and favorable safety profile of ZL-1310 in the study are positive indicators for Zai Lab's future prospects in treating extensive-stage SCLC. This could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100